Dosing and Administration
Dosing Schedule
Regardless of patient type, the dosing regimen for LUTATHERA remains the same1
Recommended Treatment Regimen with LUTATHERA1
During treatment, administer long-acting octreotide 30 mg IM between 4 to 24 hours after each dose of LUTATHERA.
aAdminister long-acting octreotide 30 mg IM between 4 to 24 hours after each dose of LUTATHERA. Do not administer long-acting octreotide within 4 weeks prior to each subsequent dose of LUTATHERA. The interval between infusions may be extended up to 16 weeks in the case of a dose modification due to an adverse reaction. Permanently discontinue LUTATHERA in patients who experience grade 3/4 hypersensitivity reactions. Please see the Prescribing Information for additional information on dose modifications.1
bContinue long-acting octreotide 30 mg IM every 4 weeks after completing LUTATHERA until disease progression or for 18 months following treatment initiation at the discretion of the physician.1
bContinue long-acting octreotide 30 mg IM every 4 weeks after completing LUTATHERA until disease progression or for 18 months following treatment initiation at the discretion of the physician.1
The recommended dose for LUTATHERA is 7.4 GBq (200 mCi) every 8 weeks (±1 week) for a total of 4 doses1
BEFORE EACH DOSE OF LUTATHERA1
 |
 |
- LUTATHERA dosage should be modified based on hematologic, renal, hepatic, hypersensitivity, or other adverse reactions (see full Prescribing Information)1
- For reduced dose administration instructions, refer to section 2.5 (Preparation and Administration) of the full Prescribing Information
GBq, gigabecquerel; IM, intramuscular; mCi, millicurie; SSAs, somatostatin analogues.